Effect of Sertraline versus Saffron capsule (SaffroMood) on the treatment of major depressive disorder in elderly

Effect of Sertraline versus Saffron capsule (SaffroMood) on the treatment of major depressive disorder in elderly: a double blind randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N204

Enrollment

Registered

2018-02-03

Start date

2018-01-20

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder. Major depressive disorder, recurrent

Interventions

Intervention 1: Intervention group: Saffron capsule (SaffroMood) 30 mg daily for 6 weeks. Intervention 2: Control group: Sertraline tablet 50 to 100 mg daily for 6 weeks.

Eligibility

Sex/Gender

All

Age

60 Years to 90 Years

Inclusion criteria

Inclusion criteria: Age of 60 to 90 years Major depressive disorder

Exclusion criteria

Exclusion criteria: Thyroid disorder Psychiatric disorders such as bipolar disorder and schizophrenia Drug abuse in the past 3 months Intention to suicide in the past year Using anti-depression drugs in the past month Electroconvulsive therapy in the past 2 months Using anticoagulant or NSAIDS

Design outcomes

Primary

Measure	Time frame
Assessing the signs and symptoms of major depressive disorder. Timepoint: Before and 6 weeks after treatment. Method of measurement: Using Hamilton questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fatemeh Ramazan Shams

Hamedan University of Medical Sciences

frsshams@yahoo.com+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026